Side-by-side · Research reference

ARA 290vsCartalax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED17/59 cited

BAnimal-MechanisticHUMAN-REVIEWED10/32 cited

ARA 290

EPO-Derived Peptide · Innate Repair Receptor Agonist

4 mgDaily doseBrines 2015 Culver 2017

28 daysPhase 2 durationCulver 2017

Non-erythropoieticSafety profileBrines 2015 Liu 2014

SQ · DailyBrines 2015 Culver 2017

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

01Mechanism of Action

Parameter

ARA 290

Cartalax

Primary target

Innate repair receptor (EPO receptor / CD131 heterodimer)

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

Pathway

EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

Downstream effect

Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014 Culver 2017

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Feedback intact?

N/A — does not interact with hematopoietic EPO receptorLiu 2014

—

Origin

11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Antibody development

Not reported in clinical trials

—

02Dosage Protocols

Parameter

ARA 290

Cartalax

Standard dose (Phase 2)

4 mg / dayBrines 2015 Culver 2017

Sarcoidosis SFN and diabetic neuropathy trials.

—

Frequency

Once daily

Self-administered subcutaneously.

—

Duration

28 days (Phase 2)Culver 2017

Corneal nerve improvements observed by day 28.

—

Evidence basis

Phase 2 RCTsCulver 2017 Brines 2015

64-subject sarcoidosis trial, type 2 diabetes trial.

Animal mechanistic studies only

Route

SubcutaneousBrines 2015

—

Timing

Any time of day

No circadian dependence reported.

—

Animal model dose

—

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

Human dosing

—

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

03Metabolic / Fat Loss Evidence

Parameter

ARA 290

Cartalax

Primary effect

Improved metabolic control (HbA1c, fasting glucose)Brines 2015

Secondary to neuropathy treatment; direct lipolytic effects not established.

—

HbA1c

Significant reduction vs placebo

Observed in type 2 diabetes + neuropathy trial.

—

Fasting glucose

Improved in ARA 290 group

—

Body composition

Not directly quantified

Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.

—

Fat loss evidence

—

None — primary target is cartilage and bone tissue, not adipose

04Side Effects & Safety

Parameter

ARA 290

Cartalax

Injection site reaction

Mild, transient

—

Hematopoiesis

None — non-erythropoietic

Distinguishes ARA 290 from native EPO.

—

Cardiovascular

No thrombotic events or hypertension reported

—

Immunogenicity

No antibody formation reported

—

Tolerability

Well-tolerated in Phase 2 trialsCulver 2017 Brines 2015

—

Documented adverse effects

—

None reported in indexed animal studies

Human safety data

—

Not available in PubMed-indexed literature

Absolute Contraindications

ARA 290

·Hypersensitivity to ARA 290

Cartalax

·Unknown due to lack of human clinical trial data

Relative Contraindications

ARA 290

·Active malignancy (theoretical EPO-axis concern; not observed in trials)

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

05Administration Protocol

Parameter

ARA 290

Cartalax

1. Preparation

Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

3. Timing

Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

4. Dosing

4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017

—

5. Storage

Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.

—

06Stack Synergy

ARA 290

+ BPC-157

Moderate

View BPC-157 →

ARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.

ARA 290: 4 mg SQ · daily
BPC-157: 250–500 mcg SQ · daily
Frequency: Once daily, same or separate injections
Primary benefit: Nerve regeneration, pain reduction, tissue healing

Cartalax

— no documented stacks